

42. The method of claim **39**, wherein the inhibitor of LRP-1 expression is administered directly to the injury.

43. The method of claim **38**, wherein the inhibitory nucleic acid is delivered in a viral vector.

44. The method of claim **38**, wherein the inhibitory nucleic acid is selecting from the group consisting of an siRNA, an shRNA, an antisense RNA, or a ribozyme.

45. The method of claim **38**, wherein the inhibitor nucleic acid is an LRP-1 specific siRNA.

46. The method of claim **38**, wherein the inhibitory nucleic acid is an LRP-1 specific siRNA comprising the nucleotide sequence of SEQ ID NO: 9.

* * * * *